ES3017684T3 - Arenavirus for use in treatment of tumors in human - Google Patents

Arenavirus for use in treatment of tumors in human Download PDF

Info

Publication number
ES3017684T3
ES3017684T3 ES16717129T ES16717129T ES3017684T3 ES 3017684 T3 ES3017684 T3 ES 3017684T3 ES 16717129 T ES16717129 T ES 16717129T ES 16717129 T ES16717129 T ES 16717129T ES 3017684 T3 ES3017684 T3 ES 3017684T3
Authority
ES
Spain
Prior art keywords
arenavirus
tumor
lcmv
cells
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717129T
Other languages
English (en)
Spanish (es)
Inventor
Karl Lang
Halime Kalkavan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abalos Therapeutics GmbH
Original Assignee
Abalos Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics GmbH filed Critical Abalos Therapeutics GmbH
Application granted granted Critical
Publication of ES3017684T3 publication Critical patent/ES3017684T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16717129T 2015-04-17 2016-04-15 Arenavirus for use in treatment of tumors in human Active ES3017684T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015207036.0A DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
PCT/EP2016/058347 WO2016166285A1 (de) 2015-04-17 2016-04-15 Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften

Publications (1)

Publication Number Publication Date
ES3017684T3 true ES3017684T3 (en) 2025-05-13

Family

ID=55759589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717129T Active ES3017684T3 (en) 2015-04-17 2016-04-15 Arenavirus for use in treatment of tumors in human

Country Status (8)

Country Link
US (3) US20180117137A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283104B1 (cg-RX-API-DMAC7.html)
JP (2) JP7039037B2 (cg-RX-API-DMAC7.html)
CN (1) CN108025054B (cg-RX-API-DMAC7.html)
CA (1) CA2982873A1 (cg-RX-API-DMAC7.html)
DE (1) DE102015207036A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017684T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016166285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
US7994221B2 (en) * 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
WO2011056993A1 (en) * 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Also Published As

Publication number Publication date
EP3283104A1 (de) 2018-02-21
CN108025054B (zh) 2022-12-23
BR112017022022A8 (pt) 2023-03-07
JP7039037B2 (ja) 2022-03-22
JP7273102B2 (ja) 2023-05-12
CN108025054A (zh) 2018-05-11
JP2021129589A (ja) 2021-09-09
CA2982873A1 (en) 2016-10-20
US11801294B2 (en) 2023-10-31
US20190151436A1 (en) 2019-05-23
WO2016166285A1 (de) 2016-10-20
DE102015207036A1 (de) 2016-10-20
HK1251168A1 (zh) 2019-01-25
JP2018515130A (ja) 2018-06-14
EP3283104C0 (de) 2024-12-11
US12409217B2 (en) 2025-09-09
US20240252611A1 (en) 2024-08-01
BR112017022022A2 (pt) 2019-01-22
US20180117137A1 (en) 2018-05-03
EP3283104B1 (de) 2024-12-11

Similar Documents

Publication Publication Date Title
CN108025054B (zh) 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
ES2759785T3 (es) Adenovirus que expresan antígenos oncógenos heterólogos
ES2265948T3 (es) Terapia para el cancer.
JP7161940B2 (ja) がんの治療のための、補体不活性化に耐性のエンベロープウイルス
US20160228541A1 (en) Papaya mosaic virus and virus-like particles in cancer therapy
CN105518149A (zh) 靶细胞内治疗性蛋白的靶向产生的系统和方法
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
JP2023509966A (ja) 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2020503390A (ja) 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
CN121775163A (zh) 促融合脂质纳米粒、制备其的方法以及其用途
KR20100122482A (ko) 항종양 효과가 있는 파라믹소바이러스
KR101911964B1 (ko) 수포성 구내염 바이러스
KR20210005637A (ko) 종양 치료용 콕삭키바이러스 b
JP2026511227A (ja) Runx3遺伝子の発現が向上したアデノ随伴ウイルス複合体及びそのkras変異肺癌の予防または治療方法
JP2020537534A (ja) 腫瘍を治療するためのエコーウイルス
CN110551197B (zh) 一种微肽及癌症治疗的药物
JP2024508823A (ja) 治療目的のための新規のウイルス粒子
HK1251168B (en) Arenavirus for use in treatment of tumors in human
BR112017022022B1 (pt) Uso de um vírus da coriomeningite linfocítica (lcmv) ou um vírus junin e composição compreende os mesmos
JP7406263B2 (ja) 改変アデノウイルス及びこれを含む医薬
CN115960906A (zh) 用于抗肿瘤免疫治疗的rna组合物、rna制剂及用途
JP2016160249A (ja) 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤
HK40122461A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants